Novartis Scemblix® shows superior major molecular

MEDIA & INVESTOR RELEASE Novartis Scemblix® shows superior major molecular response (MMR) rates vs. standard-of-care TKIs in Phase III trial for...

Related Keywords

Philadelphia , Pennsylvania , United States , Switzerland , America , Michael Meo , Zain Iqbal , Richard Jarvis , Satoshi Sugimoto , Parag Mahanti , Jonathan Graham , Imke Kappes , Isabella Zinck , Sloan Simpson , Marlena Abdinoor , Julie Masow , Novartis Scemblix , Shreeram Aradhye , Samir Shah , Tim Hughes , Nicole Zinsli Somm , Novartis , Dmax Foundation , Facebook , Exchange Commission , Australian Health Medical Research Institute , Instagram , Linkedin , Leukemia Research , South Australian Health , Medical Research Institute , Chief Medical Officer , Novartis Commitment , Term Outcomes , Imatinib Treatment , Chronic Myeloid , Year Study Results , Dasatinib Versus Imatinib Study , Chronic Myeloid Leukemia Patients , Chronic Myeloid Leukemia , Clin Adv Hematol , Versus Imatinib , Newly Diagnosed Chronic Myeloid Leukemia , Results From , Product Characteristics , Randomized Study , Provides Durable Molecular Response , Primary Efficacy , Safety Results , Allosteric Inhibitor , Tyrosine Kinase Activity , Des Devel , Reveals Significant , Durable Responses , Chronic Phase , Exhibits Safety , Phasei Study , Asciminib Plus Nilotinib , Therapy Using Asciminib Plus Imatinib , Previously Treated With , Adult Patients With Newly Diagnosed , More Tyrosine Kinase , Patients With , Treatment Optimization , Swiss Stock Exchange Novn , Novartis Pharma Ag , Media Release , D Hoc , Reimagine Medicine , Ncology , Medical Innovations ,